Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 4/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5698947 | 0.90 | TSHR (0.62) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL236551 | 0.86 | TSHR (0.52) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL105934 | 0.85 | TSHR (0.46) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL28001552 | 0.85 | TSHR (0.41) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL1064310 | 0.84 | TSHR (0.55) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL229899 | 0.84 | TSHR (0.42) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL237274 | 0.84 | TSHR (0.53) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL1065455 | 0.81 | TSHR (0.61) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL1068293 | 0.81 | TSHR (0.50) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL29270053 | 0.79 | TSHR (0.49) | TSHRHPGDALDH1A1TP53HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279441-A1 | RUBBER COMPOSITION AND TIRE | BRIDGESTONE CORPORATION (JP) | 2024-08-22 | — | — | US | disclosed |
| EP-4349902-A1 | RUBBER COMPOSITION AND TIRE | BRIDGESTONE CORPORATION (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-11530318-B2 | Rubber composition and pneumatic tire | BRIDGESTONE CORPORATION (JP) | 2022-12-20 | — | — | US | disclosed |
| WO-2022254751-A1 | RUBBER COMPOSITION AND TIRE | 株式会社ブリヂストン | 2022-12-08 | — | — | WO | disclosed |
| CN-111465645-B | Rubber composition and pneumatic tire | 株式会社普利司通 | 2022-11-15 | — | — | CN | disclosed |
| EP-3725836-B1 | RUBBER COMPOSITION AND PNEUMATIC TIRE | BRIDGESTONE CORP (JP) | 2022-08-24 | — | — | EP | disclosed |
| CN-111465645-A | Rubber composition and pneumatic tire | 株式会社普利司通 | 2020-07-28 | — | — | CN | disclosed |
| CN-108602987-B | Rubber composition and tire | 株式会社普利司通 | 2020-07-21 | — | — | CN | disclosed |
| WO-2020054484-A1 | MODIFIED MULTI-COMPONENT COPOLYMER, RUBBER COMPOSITION, RESIN COMPOSITION, TIRE AND RESIN PRODUCT | 株式会社ブリヂストン | 2020-03-19 | — | — | WO | disclosed |
| CN-104884552-B | The curable coating composition of one pack system, its preparation and application and coating prepared therefrom and product | 巴斯夫涂料有限公司 | 2018-09-14 | — | — | CN | disclosed |
| US-20130149455-A1 | CURABLE COMPOSITION AND PROCESS FOR PRODUCTION OF ORGANOSILICON COMPOUND | TOAGOSEI CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| EP-2565217-A1 | Curable composition and process for production of organosilicon compound | TOAGOSEI CO., LTD. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120045586-A1 | MOISTURE-CURING COATING COMPOSITIONS BASED ON APROTIC SOLVENTS COMPRISING BINDERS HAVING ALKOXYSILANE GROUPS AND THE USE THEREOF | BASF COATINGS GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2414466-A1 | MOISTURE-CURING COATING COMPOSITIONS BASED ON APROTIC SOLVENTS, COMPRISING BINDERS HAVING ALKOXYSILANE GROUPS, AND THE USE THEREOF | BASF Coatings GmbH (DE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2412756-A1 | CURABLE COMPOSITION | CEMEDINE CO., LTD. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120004371-A1 | CURABLE COMPOSITION | CEMEDINE CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SCHERING CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110071255-A1 | CURABLE COMPOSITION AND PROCESS FOR PRODUCTION OF ORGANOSILICON COMPOUND | TOAGOSEI CO., LTD. (JP) | 2011-03-24 | — | — | US | disclosed |
| EP-2270070-A1 | CURABLE COMPOSITION, AND PROCESS FOR PRODUCTION OF ORGANOSILICON COMPOUND | Toagosei Co., Ltd (JP) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010112106-A1 | MOISTURE-CURING COATING COMPOSITIONS BASED ON APROTIC SOLVENTS, COMPRISING BINDERS HAVING ALKOXYSILANE GROUPS, AND THE USE THEREOF | BASF COATINGS AG (DE) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | PEPD, PREP, ACE | TSHR 4342/4885HPGD 652/4885ALDH1A1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.